Myseum, Inc. (NASDAQ:MYSE – Get Free Report)’s share price was down 0.3% during trading on Wednesday . The company traded as low as $3.01 and last traded at $3.08. Approximately 200,829 shares changed hands during mid-day trading, a decline of 9% from the average daily volume of 219,570 shares. The stock had previously closed at $3.09.
Wall Street Analyst Weigh In
MYSE has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Myseum in a research note on Tuesday. Wall Street Zen lowered Myseum from a “hold” rating to a “sell” rating in a research note on Sunday, August 10th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on Myseum
Myseum Price Performance
Hedge Funds Weigh In On Myseum
An institutional investor recently bought a new position in Myseum stock. XTX Topco Ltd bought a new stake in Myseum, Inc. (NASDAQ:MYSE – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,849 shares of the company’s stock, valued at approximately $40,000. XTX Topco Ltd owned 0.32% of Myseum at the end of the most recent quarter. Institutional investors own 0.92% of the company’s stock.
Myseum Company Profile
Myseum, Inc (formerly DatChat Inc) is a security- and privacy-first social media and technology company focused on innovative and creative user platforms. Its flagship platform is Myseum, your Free Timeless Digital Shoebox Social Network that makes it easier to share your photos and videos both today, and for generations to come.
Recommended Stories
- Five stocks we like better than Myseum
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- How to Profit From Growth Investing
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- How to Capture the Benefits of Dividend Increases
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Myseum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myseum and related companies with MarketBeat.com's FREE daily email newsletter.